AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31163332 — intervention group
Group type: EXPERIMENTAL
Intervention: MI‐CBT plus treatment as usual (TAU)
Number of subjects: 44
Study 31163332 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 44
Study 28433465 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich beverage (440 kcal/300 mL)
Number of subjects: 12
Study 28433465 — intervention group
Group type: COMPARATOR
Intervention: Fat-rich beverage (440 kcal/300 mL)
Number of subjects: 12
Study 26426421 — intervention group
Group type: EXPERIMENTAL
Intervention: KM2H2 plus standard CBHCP care
Number of subjects: 450
Study 26426421 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 450
Study 23688879 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralase FS60 femtosecond laser (Group 1)
Number of subjects: 816
Study 23688879 — intervention group
Group type: COMPARATOR
Intervention: Femto LDV femtosecond laser (Group 2)
Number of subjects: 816
Study 23213766 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngopharyngeal simulator teaching
Number of subjects: 65
Study 18824845 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP levels
Number of subjects: 982
Study 17722521 — intervention group
Group type: EXPERIMENTAL
Intervention: Onion extract alone
Number of subjects: 60
Study 17722521 — intervention group
Group type: COMPARATOR
Intervention: Silicon gel sheet alone
Number of subjects: 60
Study 17722521 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of onion extract and silicon gel sheet
Number of subjects: 60
Study 15108076 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermic CPB (32 degrees C)
Number of subjects: 60
Study 15108076 — intervention group
Group type: COMPARATOR
Intervention: Normothermic CPB (>35 degrees C)
Number of subjects: 60
Study 11788126 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0
Study 11788126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10091203 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg once daily for 1 year)
Number of subjects: 1908
Study 10091203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1908
Study 10091203 — intervention group
Group type: COMPARATOR
Intervention: Alendronate and Placebo
Number of subjects: 1908
Study 7529520 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (1 x 10(6) kallikrein inactivator units (KIU) as an intravenous bolus and 1 x 10(6) KIU added to the pump prime)
Number of subjects: 20
Study 7529520 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline placebo (control group)
Number of subjects: 20
Study 2979255 — intervention group
Group type: EXPERIMENTAL
Intervention: enisoprost 100 micrograms
Number of subjects: 20
Study 2979255 — intervention group
Group type: EXPERIMENTAL
Intervention: enisoprost 200 micrograms
Number of subjects: 20
Study 2979255 — intervention group
Group type: EXPERIMENTAL
Intervention: enisoprost 400 micrograms
Number of subjects: 20
Study 2979255 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol 200 micrograms
Number of subjects: 20
Study 2979255 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 29607623 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-8500a 25 mg
Number of subjects: 84
Study 29607623 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-8500a 75 mg
Number of subjects: 84
Study 29607623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 28962590 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 733
Study 28962590 — intervention group
Group type: COMPARATOR
Intervention: CDAI (Clinical Disease Activity Index)
Number of subjects: 733
Study 28962590 — intervention group
Group type: COMPARATOR
Intervention: RAPID3 (Routine Assessment of Patient Index Data 3)
Number of subjects: 733
Study 26310621 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA) 15 mg/kg body weight
Number of subjects: 90
Study 26310621 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% sodium chloride solution)
Number of subjects: 90
Study 26310621 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 90
Study 23538970 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine ER (75‐300 mg/day)
Number of subjects: 0
Study 23538970 — intervention group
Group type: COMPARATOR
Intervention: fluoxetine (20‐60 mg/day)
Number of subjects: 0
Study 21282194 — intervention group
Group type: EXPERIMENTAL
Intervention: Clade 1 HA vaccine followed by clade 2 HA vaccine
Number of subjects: 0
Study 21282194 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated schedule (days 0 and 7)
Number of subjects: 0
Study 21282194 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule of injections at days 0 and 14
Number of subjects: 0
Study 21282194 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule of injections at days 0 and 28
Number of subjects: 0
Study 21282194 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule of injections at days 0 and 6 months
Number of subjects: 0
Study 19058584 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral penicillin (500 mg bid)
Number of subjects: 800
Study 19058584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 16553814 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei subsp. casei together with dextran
Number of subjects: 0
Study 16553814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12663340 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 parts per million (ppm) inhaled nitric oxide (NO)
Number of subjects: 40
Study 12663340 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional therapy)
Number of subjects: 40
Study 11002377 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g plant stanols at lunch
Number of subjects: 39
Study 11002377 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g plant stanols divided over three meals (0.42 g at breakfast, 0.84 g at lunch, 1.25 g at dinner)
Number of subjects: 39
Study 11002377 — intervention group
Group type: COMPARATOR
Intervention: Control (no plant stanols)
Number of subjects: 39
Study 11002377 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g plant stanols divided over three meals
Number of subjects: 39
Study 9296243 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (oral administration)
Number of subjects: 0
Study 9296243 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (aerosol dosing)
Number of subjects: 0
Study 9296243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1301850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligusticum wallichii
Number of subjects: 158
Study 1301850 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 158
Study 3815712 — intervention group
Group type: EXPERIMENTAL
Intervention: Freely-chosen stride length (FCSL)
Number of subjects: 7
Study 3815712 — intervention group
Group type: EXPERIMENTAL
Intervention: Stride length conditions (-10%, -5%, +5%, +10%)
Number of subjects: 7
Study 3815712 — intervention group
Group type: EXPERIMENTAL
Intervention: Stride length conditions
Number of subjects: 7
Study 30074934 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 201
Study 30074934 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 201
Study 27733396 — intervention group
Group type: EXPERIMENTAL
Intervention: FeSO4 (∼8 mg Fe)
Number of subjects: 457
Study 27733396 — intervention group
Group type: EXPERIMENTAL
Intervention: NaFeEDTA (∼8 mg Fe, ∼41 mg EDTA)
Number of subjects: 457
Study 27733396 — intervention group
Group type: EXPERIMENTAL
Intervention: Na2EDTA (∼41 mg EDTA)
Number of subjects: 457
Study 27733396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study 24485481 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 19
Study 24485481 — intervention group
Group type: COMPARATOR
Intervention: Control group (no meditation)
Number of subjects: 19
Study 23413494 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-layer bandage system (KTwo)
Number of subjects: 187
Study 23413494 — intervention group
Group type: COMPARATOR
Intervention: Four-layer bandage system (Profore)
Number of subjects: 187
Study 20147616 — intervention group
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Number of subjects: 0
Study 18405977 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric step muscle actions at 5% MVC
Number of subjects: 19
Study 18405977 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric ramp muscle actions at 35% MVC
Number of subjects: 19
Study 18405977 — intervention group
Group type: EXPERIMENTAL
Intervention: MMG RMS
Number of subjects: 19
Study 18405977 — intervention group
Group type: EXPERIMENTAL
Intervention: MMG MPF
Number of subjects: 19
Study 18405977 — intervention group
Group type: EXPERIMENTAL
Intervention: MMG RMS and MMG MPF
Number of subjects: 19
Study 16548860 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen for 10 min
Number of subjects: 54
Study 16548860 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% sevoflurane in 100% oxygen
Number of subjects: 54
Study 16548860 — intervention group
Group type: COMPARATOR
Intervention: Air breathing for 10 min
Number of subjects: 54
Study 12797340 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 128 g/day
Number of subjects: 22
Study 12797340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10836006 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment for noncomplicated colon and rectal cancer
Number of subjects: 0
Study 10836006 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for colon adenocarcinoma and rectal cancer
Number of subjects: 0
Study 10836006 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for complicated colorectal cancer
Number of subjects: 0
Study 9369890 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration
Number of subjects: 30
Study 9369890 — intervention group
Group type: COMPARATOR
Intervention: No hemofiltration (Control)
Number of subjects: 30
Study 1562865 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care
Number of subjects: 120
Study 1562865 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 120
Study 3931806 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postoperative radiotherapy
Number of subjects: 1461
Study 3931806 — intervention group
Group type: COMPARATOR
Intervention: Optional delayed radiotherapy policy (watched group)
Number of subjects: 1461
Study 31795035 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1008
Study 31795035 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1008
Study 31795035 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-extended release
Number of subjects: 1008
Study 31795035 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram or Sertraline (females only)
Number of subjects: 1008
Study 29499658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (three home visits)
Number of subjects: 201
Study 29499658 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 201
Study 27956398 — intervention group
Group type: COMPARATOR
Intervention: AF initiation
Number of subjects: 45
Study 25099201 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reduction of risperidone or olanzapine (dose reduced by 50%)
Number of subjects: 31
Study 25099201 — intervention group
Group type: COMPARATOR
Intervention: Maintenance group (dose kept constant)
Number of subjects: 31
Study 22520568 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional maxillary distraction osteogenesis
Number of subjects: 10
Study 22520568 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior maxillary segmental distraction
Number of subjects: 10
Study 18702064 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based relationship enhancement (RE)
Number of subjects: 14
Study 18702064 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 14
Study 17488138 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacist-led medicines management service
Number of subjects: 1480
Study 17488138 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 1480
Study 15258006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (10 mg daily)
Number of subjects: 24
Study 11236522 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis for 2-3 hours, started as early as possible after administration of CM (106 +/- 25 minutes)
Number of subjects: 15
Study 11236522 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 15
Study 11236522 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis
Number of subjects: 15
Study 9766780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment of residual symptoms
Number of subjects: 40
Study 9766780 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical management
Number of subjects: 40
Study 8142192 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 759
Study 3415890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve blockade
Number of subjects: 0
Study 3415890 — intervention group
Group type: COMPARATOR
Intervention: i.m. papaveretum
Number of subjects: 0
Study 30536713 — intervention group
Group type: COMPARATOR
Intervention: Placebo after 5 years of alendronate
Number of subjects: 0
Study 30536713 — intervention group
Group type: COMPARATOR
Intervention: Continued treatment after 3 years of zoledronic acid
Number of subjects: 0
Study 30536713 — intervention group
Group type: EXPERIMENTAL
Intervention: FLEX group
Number of subjects: 0
Study 30536713 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study 28431515 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Life Story Book (OLSB) intervention, guided by a trained volunteer over 5 meetings within 8-10 weeks
Number of subjects: 0
Study 28431515 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control condition)
Number of subjects: 0
Study 26317819 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH every 8 hours
Number of subjects: 495
Study 26317819 — intervention group
Group type: COMPARATOR
Intervention: enoxaparin every 12 hours
Number of subjects: 495
Study 24188204 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 100 μg plus oral procaterol 25 μg
Number of subjects: 159
Study 24188204 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 100 μg plus placebo
Number of subjects: 159
Study 20473216 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-centered physical activity skill development program (Activity)
Number of subjects: 165
Study 20473216 — intervention group
Group type: COMPARATOR
Intervention: Parent-centered dietary modification program (DIET)
Number of subjects: 165
Study 20473216 — intervention group
Group type: EXPERIMENTAL
Intervention: Both programs combined (PA+DIET)
Number of subjects: 165
Study 20473216 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Activity, DIET, PA+DIET)
Number of subjects: 165
Study 19001475 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 7599
Study 19001475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7599
Study 19001475 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan or Placebo
Number of subjects: 7599
Study 16733947 — intervention group
Group type: EXPERIMENTAL
Intervention: Forgiveness training program (8 weeks)
Number of subjects: 25
Study 16733947 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-listed)
Number of subjects: 25
Study 15210673 — intervention group
Group type: COMPARATOR
Intervention: Healthy infants (control group)
Number of subjects: 162
Study 15210673 — intervention group
Group type: EXPERIMENTAL
Intervention: Sick infants
Number of subjects: 162
Study 15210673 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression model
Number of subjects: 162
Study 11293640 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg, four times daily for 10 days)
Number of subjects: 4826
Study 11293640 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav (325 mg, four times daily for 10 days)
Number of subjects: 4826
Study 11293640 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav plus erythromycin
Number of subjects: 4826
Study 9272793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.15 mg/kg
Number of subjects: 12
Study 9272793 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.15 mg/kg
Number of subjects: 12
Study 9272793 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 12
Study 8346863 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine
Number of subjects: 0
Study 8346863 — intervention group
Group type: EXPERIMENTAL
Intervention: diphenhydramine
Number of subjects: 0
Study 8346863 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo
Number of subjects: 0
Study 8346863 — intervention group
Group type: COMPARATOR
Intervention: normal controls
Number of subjects: 0
Study 3568540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 90 mg
Number of subjects: 155
Study 3568540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 155
Study 3568540 — intervention group
Group type: COMPARATOR
Intervention: Morphine 6 mg
Number of subjects: 155
Study 3568540 — intervention group
Group type: COMPARATOR
Intervention: Morphine 12 mg
Number of subjects: 155
Study 30783649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 0
Study 30783649 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/cobicistat
Number of subjects: 0
Study 30783649 — intervention group
Group type: EXPERIMENTAL
Intervention: All antiretroviral drugs
Number of subjects: 0
Study 28188678 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stent removal at 5 days (without cystoscopy)
Number of subjects: 205
Study 28188678 — intervention group
Group type: COMPARATOR
Intervention: Late stent removal at 6 weeks (with cystoscopy)
Number of subjects: 205
Study 25940060 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial shock wave therapy plus plantar fascia-specific stretching (Group 2, n = 79)
Number of subjects: 152
Study 25940060 — intervention group
Group type: COMPARATOR
Intervention: Radial shock wave therapy alone (Group 1, n = 73)
Number of subjects: 152
Study 23287551 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality simulation (VRS)
Number of subjects: 0
Study 23287551 — intervention group
Group type: COMPARATOR
Intervention: Web-based modules (Control group)
Number of subjects: 0
Study 22030569 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections with retractable fixed syringes and needles
Number of subjects: 1240
Study 22030569 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injections with no needles combined
Number of subjects: 1240
Study 22030569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections with retractable fixed syringes and needles
Number of subjects: 1240
Study 22030569 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injections with no needles combined
Number of subjects: 1240
Study 17614027 — intervention group
Group type: EXPERIMENTAL
Intervention: Running with no fluid (NF)
Number of subjects: 20
Study 17614027 — intervention group
Group type: COMPARATOR
Intervention: Running with ingestion of a 4 % glucose solution (GLU)
Number of subjects: 20
Study 17614027 — intervention group
Group type: COMPARATOR
Intervention: Running with ingestion of a water placebo (PLA)
Number of subjects: 20
Study 17614027 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 20
Study 16941885 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity laser treatment
Number of subjects: 0
Study 14550821 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg everolimus twice daily
Number of subjects: 634
Study 14550821 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg everolimus twice daily
Number of subjects: 634
Study 14550821 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 634
Study 10932507 — intervention group
Group type: EXPERIMENTAL
Intervention: Infertile men
Number of subjects: 40
Study 10932507 — intervention group
Group type: COMPARATOR
Intervention: Normal men
Number of subjects: 40
Study 8823459 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU per kg of rHuEPO subcutaneously twice a week for 2 weeks
Number of subjects: 52
Study 8823459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 1389934 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (10-50 mg a day)
Number of subjects: 9
Study 1389934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1389934 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxycodone (0.28 mg kg-1)
Number of subjects: 9
Study 1389934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular oxycodone (0.14 mg kg-1)
Number of subjects: 9
Study 1389934 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 9
Study 1389934 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 9
Study 1389934 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone
Number of subjects: 9
Study 1389934 — intervention group
Group type: EXPERIMENTAL
Intervention: Noroxycodone
Number of subjects: 9
Study 3917584 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-intensive stroke unit
Number of subjects: 293
Study 3917584 — intervention group
Group type: COMPARATOR
Intervention: General medical wards
Number of subjects: 293
Study 31926466 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant
Number of subjects: 2061
Study 31926466 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol
Number of subjects: 2061
Study 31926466 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective TST and subjective number of awakenings
Number of subjects: 2061
Study 31926466 — intervention group
Group type: COMPARATOR
Intervention: PSG variables plus patient's age and gender
Number of subjects: 2061